Navigation Links
Northwest Biotherapeutics Secures $700,000 Equity Financing
Date:2/10/2009

BETHESDA, Md., Feb. 10 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC Bulletin Board: NWBO) (the "Company") announces today receipt of $700,000 in cash from Al Rajhi Holdings through the subscription of 1,000,000 new shares in the form of the Company's common stock at $0.70 per share. The new stock is expected to be admitted to trading on AIM on 16 February 2009. The shares will not be tradable on the Company's OTC bulletin board listing in the US without prior registration. The proceeds will be used to support the Company's ongoing working capital needs.

"We are very pleased to have completed another interim financing despite severely adverse general market conditions," said NWBT's Chief Executive Officer Alton Boynton. "We look forward to continuing the financing discussions currently under way with several additional parties for short-term and long-term funding of the Company".

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.

For further information, please visit the company web site at http://www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated. Additional information on these and other factors, which could affect the company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the company's SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
2. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
3. Northwest Secures US$1.65 Million Debt Financing
4. Northwest Secures US$1.0 Million Debt Financing
5. Northwestern chemists take gold, mass-produce Beijing Olympic logo
6. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
7. Northwestern chemist investigates lost reds in Homer painting
8. Nikon Instruments Opens New Imaging Center at Northwestern University
9. Northwest Secures US$4.0 Million in Debt Financing
10. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
11. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016 Despite ... see value in this space. Today,s pre-market research on ActiveWallSt.com ... Radius Health Inc. (NASDAQ: RDUS ), Cerus Corp. ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... technical briefings at: http://www.activewallst.com/ ...
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board ... BIO 2016 in San Francisco. Located at booth number 7301, representatives from the ... questions and discuss the Thai biotechnology and life sciences sector. , Deputy ...
(Date:5/25/2016)... , ... May 25, 2016 , ... WEDI, the nation’s ... exchange, today announced that Charles W. Stellar has been named by the WEDI Board ... since January 2016. As an executive leader with more than 35 years of experience ...
(Date:5/24/2016)... La Jolla, CA (PRWEB) , ... May 24, 2016 , ... ... and financial planning for corporate executives and entrepreneurs, held The Future of San Diego ... leaders in the San Diego life science community attended the event with speakers Dr. ...
Breaking Biology Technology:
(Date:3/21/2016)... , March 22, 2016 ... recognition with passcodes for superior security   ... a leading provider of secure digital communications services, today ... biometric technology and offer enterprise customers, particularly those in ... facial recognition and voice authentication within a mobile app, ...
(Date:3/14/2016)... Florida , March 14, 2016 ... the growing mobile commerce market, announces the airing of a ... channels starting the week of March 21 st .  The ... CNBC, including its popular Squawk on the Street show. ... focused on the growing mobile commerce market, announces the airing ...
(Date:3/10/2016)... BLUE BELL, Pa. , March 10, 2016   ... U.S. Customs and Border Protection (CBP) is testing ... in San Diego to help identify ... United States . The test, designed to help determine ... outdoor, pedestrian environment, began in February and will run until ...
Breaking Biology News(10 mins):